Course Schedule and Structure

Course Structure

This course incorporates various delivery methods in order to provide you with some key theoretical fundamentals for psychedelic-assisted therapy, using an evidence-based approach and best practices that will promote your learning retention and engagement. We aim to provide you with sufficient opportunities to practice relevant skills that will help you on your journey to becoming a competent clinician with psychedelic-assisted therapy.

Asynchronous Online Content

Each week, you will need to complete all the online content prior to attending the virtual class session. In the online content, there is text for you to read, videos for you to watch, podcasts for you to listen to, and small activities for you to complete to practice your skills and check your understanding. You can expect this to take 2.5-3 hours each week.

Virtual Classes

The primary goal of the virtual classes is to practice the key skills and competenciesusing the online material as your foundation. Please come to class with the intention of participating and engaging with your fellow therapists in order to get the most out of these sessions.

Assessments

Throughout the course, there will be various assessments to evaluate your knowledge, skills, and competencies that you have gained from the course. On the upcoming Assessment Overview page, you will learn about the course assessments and what you’ll need to successfully complete them.

Practice Groups

You will be assigned to a group of 3 therapists. Each week, you should meet for 30 minutes at a time most convenient to you. You will be given some skills and competencies to practice each week. In your triad, you will take turns playing the role of therapist, client, and observer. These groups are excellent opportunities to further practice skills beyond the virtual classes as well as network with likeminded therapists. If at any point you are having challenges in these groups, please reach out to training@numinus.com for support.

Course Schedule

Before we dive into the course content, take a look at the course schedule to give yourself an idea of what is expected of you each week.

Course Start Date

Tuesday October 11, 2022

Course End Date

Sunday December 4, 2022

Final Assignment Submission Date

Sunday December 11, 2022 at 11:59PM PT

Monday December 12, 2022 at2:59PM ET

Time Zones

If you are not located in the Pacific or Eastern Time Zone, please refer to the Time Zone Converter to ensure that you don’t miss deadlines or any virtual classes.

Tuesday October 11, 2022 to Sunday October 16, 2022

Asynchronous Topics

  • Introduction to the course

  • Overview of Psychedelic-Assisted Therapy

  • Brief history of psychedelic medicines

  • Introduction to the Numinus care model

Learning Outcomes

  • Commit to applying the seven guiding approaches when conducting psychedelic-assisted therapy in the Numinus care model.

  • Justify the prioritization of integrative and transformative mental wellness within the context of psychedelic-assisted therapy by contrasting it with conventional mental health treatment approaches.

  • Describe the mission, vision, and values of Numinus.

  • Differentiate the outcomes of the psilocybin, MDMA, and Ketamine psychedelic-assisted therapy from a high-level.

  • Explain the structure of psychedelic-assisted therapy.

  • Describe key historical research that has contributed to the development of current psychedelic-assisted therapy methods.

  • Explain the impact ofThe Controlled Drug and Substances Act & Special Access Programme (SAP) in Canada, and The Controlled Substances Act in the United States on psychedelic research and current drug policy.

Virtual Classes

  • Thursday October 13 at hh:mm PT/hh:mm ET

Assessments

  • Module 1 Knowledge Check must be completed by Sunday October 16 at 11:59PM PT/Monday October 17 at 2:59AM ET.

Monday October 17, 2022 to Sunday October 23, 2022

Asynchronous Topics

  • Introduction to the course

  • Overview of Psychedelic-Assisted Therapy

  • Brief history of psychedelic medicines

  • Introduction to the Numinus care model

Learning Outcomes

  • Commit to applying the seven guiding approaches when conducting psychedelic-assisted therapy in the Numinus care model.

  • Justify the prioritization of integrative and transformative mental wellness within the context of psychedelic-assisted therapy by contrasting it with conventional mental health treatment approaches.

  • Describe the mission, vision, and values of Numinus.

  • Differentiate the outcomes of the psilocybin, MDMA, and Ketamine psychedelic-assisted therapy from a high-level.

  • Explain the structure of psychedelic-assisted therapy.

  • Describe key historical research that has contributed to the development of current psychedelic-assisted therapy methods.

  • Explain the impact ofThe Controlled Drug and Substances Act & Special Access Programme (SAP) in Canada, and The Controlled Substances Act in the United States on psychedelic research and current drug policy.

Virtual Classes

  • Thursday October 13 at hh:mm PT/hh:mm ET

Assessments

  • Module 2 Knowledge Check must be completed by Sunday October 23 at 11:59PM PT/Monday October 24 at 2:59AM ET.

Monday October 24, 2022 to Sunday October 30, 2022

Asynchronous Topics

  • Introduction to the course

  • Overview of Psychedelic-Assisted Therapy

  • Brief history of psychedelic medicines

  • Introduction to the Numinus care model

Learning Outcomes

  • Commit to applying the seven guiding approaches when conducting psychedelic-assisted therapy in the Numinus care model.

  • Justify the prioritization of integrative and transformative mental wellness within the context of psychedelic-assisted therapy by contrasting it with conventional mental health treatment approaches.

  • Describe the mission, vision, and values of Numinus.

  • Differentiate the outcomes of the psilocybin, MDMA, and Ketamine psychedelic-assisted therapy from a high-level.

  • Explain the structure of psychedelic-assisted therapy.

  • Describe key historical research that has contributed to the development of current psychedelic-assisted therapy methods.

  • Explain the impact ofThe Controlled Drug and Substances Act & Special Access Programme (SAP) in Canada, and The Controlled Substances Act in the United States on psychedelic research and current drug policy.

Virtual Classes

  • Thursday October 13 at hh:mm PT/hh:mm ET

Assessments

  • Module 3 Knowledge Check must be completed by Sunday October 30 at 11:59PM PT/Monday October 31 at 2:59AM ET.

Monday October 31, 2022 to Sunday November 6, 2022

Asynchronous Topics

  • Introduction to the course

  • Overview of Psychedelic-Assisted Therapy

  • Brief history of psychedelic medicines

  • Introduction to the Numinus care model

Learning Outcomes

  • Commit to applying the seven guiding approaches when conducting psychedelic-assisted therapy in the Numinus care model.

  • Justify the prioritization of integrative and transformative mental wellness within the context of psychedelic-assisted therapy by contrasting it with conventional mental health treatment approaches.

  • Describe the mission, vision, and values of Numinus.

  • Differentiate the outcomes of the psilocybin, MDMA, and Ketamine psychedelic-assisted therapy from a high-level.

  • Explain the structure of psychedelic-assisted therapy.

  • Describe key historical research that has contributed to the development of current psychedelic-assisted therapy methods.

  • Explain the impact ofThe Controlled Drug and Substances Act & Special Access Programme (SAP) in Canada, and The Controlled Substances Act in the United States on psychedelic research and current drug policy.

Virtual Classes

  • Thursday October 13 at hh:mm PT/hh:mm ET

Assessments

  • Module 4 Knowledge Check must be completed by Sunday November 6 at 11:59PM PT/Monday November 7 at 2:59AM ET.

Monday November 7, 2022 to Sunday November 13, 2022

Asynchronous Topics

  • Introduction to the course

  • Overview of Psychedelic-Assisted Therapy

  • Brief history of psychedelic medicines

  • Introduction to the Numinus care model

Learning Outcomes

  • Commit to applying the seven guiding approaches when conducting psychedelic-assisted therapy in the Numinus care model.

  • Justify the prioritization of integrative and transformative mental wellness within the context of psychedelic-assisted therapy by contrasting it with conventional mental health treatment approaches.

  • Describe the mission, vision, and values of Numinus.

  • Differentiate the outcomes of the psilocybin, MDMA, and Ketamine psychedelic-assisted therapy from a high-level.

  • Explain the structure of psychedelic-assisted therapy.

  • Describe key historical research that has contributed to the development of current psychedelic-assisted therapy methods.

  • Explain the impact ofThe Controlled Drug and Substances Act & Special Access Programme (SAP) in Canada, and The Controlled Substances Act in the United States on psychedelic research and current drug policy.

Virtual Classes

  • Thursday October 13 at hh:mm PT/hh:mm ET

Assessments

  • Module 5 Knowledge Check must be completed by Sunday November 13 at 11:59PM PT/Monday November 14 at 2:59AM ET.

Monday November 14, 2022 to Sunday November 20, 2022

Asynchronous Topics

  • Introduction to the course

  • Overview of Psychedelic-Assisted Therapy

  • Brief history of psychedelic medicines

  • Introduction to the Numinus care model

Learning Outcomes

  • Commit to applying the seven guiding approaches when conducting psychedelic-assisted therapy in the Numinus care model.

  • Justify the prioritization of integrative and transformative mental wellness within the context of psychedelic-assisted therapy by contrasting it with conventional mental health treatment approaches.

  • Describe the mission, vision, and values of Numinus.

  • Differentiate the outcomes of the psilocybin, MDMA, and Ketamine psychedelic-assisted therapy from a high-level.

  • Explain the structure of psychedelic-assisted therapy.

  • Describe key historical research that has contributed to the development of current psychedelic-assisted therapy methods.

  • Explain the impact ofThe Controlled Drug and Substances Act & Special Access Programme (SAP) in Canada, and The Controlled Substances Act in the United States on psychedelic research and current drug policy.

Virtual Classes

  • Thursday October 13 at hh:mm PT/hh:mm ET

Assessments

  • Module 6 Knowledge Check must be completed by Sunday November 20 at 11:59PM PT/Monday November 21 at 2:59AM ET.

Monday November 21, 2022 to Sunday November 27, 2022

Asynchronous Topics

  • Introduction to the course

  • Overview of Psychedelic-Assisted Therapy

  • Brief history of psychedelic medicines

  • Introduction to the Numinus care model

Learning Outcomes

  • Commit to applying the seven guiding approaches when conducting psychedelic-assisted therapy in the Numinus care model.

  • Justify the prioritization of integrative and transformative mental wellness within the context of psychedelic-assisted therapy by contrasting it with conventional mental health treatment approaches.

  • Describe the mission, vision, and values of Numinus.

  • Differentiate the outcomes of the psilocybin, MDMA, and Ketamine psychedelic-assisted therapy from a high-level.

  • Explain the structure of psychedelic-assisted therapy.

  • Describe key historical research that has contributed to the development of current psychedelic-assisted therapy methods.

  • Explain the impact ofThe Controlled Drug and Substances Act & Special Access Programme (SAP) in Canada, and The Controlled Substances Act in the United States on psychedelic research and current drug policy.

Virtual Classes

  • Thursday October 13 at hh:mm PT/hh:mm ET

Assessments

  • Module 7 Knowledge Check must be completed by Sunday November 27 at 11:59PM PT/Monday November 28 at 2:59AM ET.

Monday November 28, 2022 to Sunday December 4, 2022

Asynchronous Topics

  • Introduction to the course

  • Overview of Psychedelic-Assisted Therapy

  • Brief history of psychedelic medicines

  • Introduction to the Numinus care model

Learning Outcomes

  • Commit to applying the seven guiding approaches when conducting psychedelic-assisted therapy in the Numinus care model.

  • Justify the prioritization of integrative and transformative mental wellness within the context of psychedelic-assisted therapy by contrasting it with conventional mental health treatment approaches.

  • Describe the mission, vision, and values of Numinus.

  • Differentiate the outcomes of the psilocybin, MDMA, and Ketamine psychedelic-assisted therapy from a high-level.

  • Explain the structure of psychedelic-assisted therapy.

  • Describe key historical research that has contributed to the development of current psychedelic-assisted therapy methods.

  • Explain the impact ofThe Controlled Drug and Substances Act & Special Access Programme (SAP) in Canada, and The Controlled Substances Act in the United States on psychedelic research and current drug policy.

Virtual Classes

  • Thursday October 13 at hh:mm PT/hh:mm ET

Assessments

  • Module 8 Knowledge Check must be completed by Sunday December 4 at 11:59PM PT/Monday December 5 at 2:59AM ET.